Advertisement
Screener

Neurogene Inc. (NGNE) Restructuring Charges

2.8 / 5 stars · 68/120 Roast Me

Neurogene Inc. Restructuring Charges

Neurogene Inc. (NGNE) reported Restructuring Charges of $2.11 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.

Discontinued › Expense Statement › Operating Expenses

us-gaap:RestructuringCharges · last filed 2023-11-14

  • Neurogene Inc. restructuring charges for the quarter ending 2023-09-30 was $0.00.
  • Neurogene Inc. restructuring charges for the quarter ending 2023-06-30 was $142.00K.
  • Neurogene Inc. restructuring charges for the quarter ending 2023-03-31 was $1.97M.
  • Neurogene Inc. restructuring charges for fiscal 2022 was $1.41M.
  • Neurogene Inc. restructuring charges for fiscal 2020 was $0.00.
Period endRestructuring Charges 3 monthRestructuring Charges 6 monthRestructuring Charges 9 monthRestructuring Charges 12 month
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$142.00K
derived: sum of 2 quarters · filed 2023-11-14
$2.11M
10-Q · filed 2023-11-14
2023-06-30$142.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$2.11M
10-Q · filed 2023-08-10
2023-03-31$1.97M
10-Q · filed 2023-05-08
2022-12-31$1.41M
10-K · filed 2023-03-20
2020-12-31$0.00
10-K · filed 2021-03-25
2018-09-30$9.15M
10-Q · filed 2018-11-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76